Cargando…

Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study

Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular complication of diabetes. Our study was to assess prevalence and risk factors for DPN in subjects with type 2 diabetes from 14 different countries. Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yanhui, Xing, Pengbo, Cai, Xue, Luo, Dan, Li, Ruxue, Lloyd, Cathy, Sartorius, Norman, Li, Mingzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606804/
https://www.ncbi.nlm.nih.gov/pubmed/33194943
http://dx.doi.org/10.3389/fpubh.2020.534372
_version_ 1783604513847902208
author Lu, Yanhui
Xing, Pengbo
Cai, Xue
Luo, Dan
Li, Ruxue
Lloyd, Cathy
Sartorius, Norman
Li, Mingzi
author_facet Lu, Yanhui
Xing, Pengbo
Cai, Xue
Luo, Dan
Li, Ruxue
Lloyd, Cathy
Sartorius, Norman
Li, Mingzi
author_sort Lu, Yanhui
collection PubMed
description Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular complication of diabetes. Our study was to assess prevalence and risk factors for DPN in subjects with type 2 diabetes from 14 different countries. Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45.3% men, mean duration of diabetes = 8.8 years) were included to perform this International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study in 14 countries. After a structured questionnaire was used in face-to-face interviews to collect sociodemographic characteristics and medical records of the participating subjects, laboratory tests were carried out for clinical measurement. Depressive symptoms were diagnosed and measured using the Patient Health Questionnaire-9. The potential risk factors for DPN were determined by multilevel mixed-effects logistic regression, accounting for clustering of participants within the country. Robustness of the estimates was assessed by sensitivity analysis. Results: The overall prevalence of DPN across different countries was 26.71%, whereas country-specific prevalences showed considerable variation. Multivariate analysis revealed that duration of diabetes (OR: 1.08 per 1-year increase, 95% CI: 1.06–1.09), poor glycemic control (OR: 1.11 per 1% increase in HbA1c, 95% CI: 1.05–1.18), and history of hypertension (OR: 1.58, 95% CI: 1.18–2.12), cardiovascular disease (OR: 2.07, 95% CI: 1.55–2.78) and depressive symptoms (OR: 1.92, 95% CI: 1.43–2.58) were independently and positively associated with the risk of DPN. Sensitivity analyses including or excluding patients from countries with extreme low or high prevalence of DPN yielded similar estimates in terms of trend and magnitude. Conclusions: This international study illustrates that more than a quarter of individuals with type 2 diabetes developed DPN. The prevalence was positively associated with the duration of diabetes, poor glycemic control, and history of hypertension, cardiovascular disease and depressive symptoms.
format Online
Article
Text
id pubmed-7606804
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76068042020-11-13 Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study Lu, Yanhui Xing, Pengbo Cai, Xue Luo, Dan Li, Ruxue Lloyd, Cathy Sartorius, Norman Li, Mingzi Front Public Health Public Health Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular complication of diabetes. Our study was to assess prevalence and risk factors for DPN in subjects with type 2 diabetes from 14 different countries. Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45.3% men, mean duration of diabetes = 8.8 years) were included to perform this International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study in 14 countries. After a structured questionnaire was used in face-to-face interviews to collect sociodemographic characteristics and medical records of the participating subjects, laboratory tests were carried out for clinical measurement. Depressive symptoms were diagnosed and measured using the Patient Health Questionnaire-9. The potential risk factors for DPN were determined by multilevel mixed-effects logistic regression, accounting for clustering of participants within the country. Robustness of the estimates was assessed by sensitivity analysis. Results: The overall prevalence of DPN across different countries was 26.71%, whereas country-specific prevalences showed considerable variation. Multivariate analysis revealed that duration of diabetes (OR: 1.08 per 1-year increase, 95% CI: 1.06–1.09), poor glycemic control (OR: 1.11 per 1% increase in HbA1c, 95% CI: 1.05–1.18), and history of hypertension (OR: 1.58, 95% CI: 1.18–2.12), cardiovascular disease (OR: 2.07, 95% CI: 1.55–2.78) and depressive symptoms (OR: 1.92, 95% CI: 1.43–2.58) were independently and positively associated with the risk of DPN. Sensitivity analyses including or excluding patients from countries with extreme low or high prevalence of DPN yielded similar estimates in terms of trend and magnitude. Conclusions: This international study illustrates that more than a quarter of individuals with type 2 diabetes developed DPN. The prevalence was positively associated with the duration of diabetes, poor glycemic control, and history of hypertension, cardiovascular disease and depressive symptoms. Frontiers Media S.A. 2020-10-20 /pmc/articles/PMC7606804/ /pubmed/33194943 http://dx.doi.org/10.3389/fpubh.2020.534372 Text en Copyright © 2020 Lu, Xing, Cai, Luo, Li, Lloyd, Sartorius and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Lu, Yanhui
Xing, Pengbo
Cai, Xue
Luo, Dan
Li, Ruxue
Lloyd, Cathy
Sartorius, Norman
Li, Mingzi
Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
title Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
title_full Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
title_fullStr Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
title_full_unstemmed Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
title_short Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
title_sort prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the interpret-dd study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606804/
https://www.ncbi.nlm.nih.gov/pubmed/33194943
http://dx.doi.org/10.3389/fpubh.2020.534372
work_keys_str_mv AT luyanhui prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT xingpengbo prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT caixue prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT luodan prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT liruxue prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT lloydcathy prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT sartoriusnorman prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy
AT limingzi prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy